-
Study aim
-
Investigation of the effect of inhaled heparin in the treatment of patients with adult respiratory distress syndrome
-
Design
-
In this study, 60 blind two-way ARDS intubation blind clinical trial trials were randomly divided into two groups of intervention and control.
-
Settings and conduct
-
In this study, 60 ARSD patients were selected as available in the ICU of Golestan Hospital in Ahvaz and were divided into two groups of intervention and control in a simple random manner. Patients of the intervention group, 5000 units of heparin in the nebulizer are inhaled every 12 hours for 7 days and used for patients of the normal saline control group. They were informed.
-
Participants/Inclusion and exclusion criteria
-
criteria include:Patients 18 to 60 years, Under mechanical ventilation for more than 48 hours, Respiratory index PAO2 / FIO2 ≤200 mmhg, Bilateral pulmonary infiltration in the chest x-ray, Lack of heart disease and previous lung disease Positive end expiratory pressure or PEEP≥ ventilator 5 cmh2, No history of intracerebral hemorrhage in the past 12 months and No history of heparin-induced thrombocytopenia.
Non-entry criteria: Dissatisfaction to continue working on the study, Hypersensitivity to heparin, Uncontrolled bleeding or bleeding disorders, PTT and INR impaired and Patients receiving therapeutic doses of heparin, anaxaparin and warfarin.
-
Intervention groups
-
Patients of the intervention group, 5,000 units every 12 hours for 7 days and used for patients of normal saline control group. It is then connected to a ventilator.
-
Main outcome variables
-
In addition to vital signs and alertness levels, PAO2 / FIO2, ABG, Pao2, Pulmonary Shant Percentage, Sao2, PEEP, hospital stay time, time required for mechanical ventilation, 48-hour, 7-day mortality rate, and lung capacity of patients , Tidal Volume, Respiratory rate, Minute Ventilation, Paco2 were recorded during the 7-day study period.